1-5 of 5
Cathy D. Williams, MBBS, MCRP, FRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 1884.
https://doi.org/10.1182/blood.V122.21.1884.1884
Published: 2013
Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3378.
https://doi.org/10.1182/blood.V122.21.3378.3378
Published: 2013
Journal Articles

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Stephen A Schey, MD, Kwee L Yong, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, Faith E Davies, MD, Gareth J Morgan, MD PhD, James D. Cavenagh, MD, Gordon Cook, MD, PhD, Mark Cook, Avie-Lee Coney, Sarah Brown, PhD, Louise M Flanagan, PhD, Walter Gregory, PhD, Jim Cavet, FRCPath
Journal: Blood
Blood (2013) 122 (21): 286.
https://doi.org/10.1182/blood.V122.21.286.286
Published: 2013
Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 765.
https://doi.org/10.1182/blood.V122.21.765.765
Published: 2013
Journal Articles

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid ® Treatment Continuation Scheme™ (TCS)

Cathy D. Williams, MBBS, MCRP, FRCPath, Mathew Simcock, MSc, Imran Lodhi, MBBS, Suzanne K. Robinson, PhD, Faith E. Davies, MD
Journal: Blood
Blood (2012) 120 (21): 4067.
https://doi.org/10.1182/blood.V120.21.4067.4067
Published: 2012